Sleeping Sickness Disrupts the Sleep-Regulating Adenosine System 2 3 Short Title: Sleeping Sickness and Adenosine 4 5 Filipa Rijo-Ferreira*1,2, Theresa E

Total Page:16

File Type:pdf, Size:1020Kb

Sleeping Sickness Disrupts the Sleep-Regulating Adenosine System 2 3 Short Title: Sleeping Sickness and Adenosine 4 5 Filipa Rijo-Ferreira*1,2, Theresa E Research Articles: Neurobiology of Disease Sleeping sickness disrupts the sleep- regulating adenosine system https://doi.org/10.1523/JNEUROSCI.1046-20.2020 Cite as: J. Neurosci 2020; 10.1523/JNEUROSCI.1046-20.2020 Received: 30 April 2020 Revised: 28 September 2020 Accepted: 11 October 2020 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2020 the authors 1 Title: Sleeping sickness disrupts the sleep-regulating adenosine system 2 3 Short title: Sleeping sickness and adenosine 4 5 Filipa Rijo-Ferreira*1,2, Theresa E. Bjorness*3,4, Kimberly H. Cox1, Alex Sonneborn1,3, 6 Robert W. Greene1,3, and Joseph S. Takahashi1,2,# 7 8 1 Department of Neuroscience, Peter O’Donnell Jr. Brain Institute, University of Texas 9 Southwestern Medical Center, Dallas, TX 75390-9111, USA 10 2 Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, 11 Dallas, TX 75390-9111, USA 12 3 Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, 13 TX 75390-9111, USA 14 4Research Service, VA North Texas Health Care System, Dallas, TX 75126 15 16 * co-authors 17 18 # Correspondence: [email protected] 19 20 21 Number of pages: 32 22 23 Number of figures: 7 24 25 Number of tables: 1 26 27 Number of words for abstract: 130 28 29 Number of words for introduction: 588 30 31 Number of words for discussion: 1259 32 33 Conflict of Interest Statement: The authors have nothing to declare. 34 35 Acknowledgements: We would like to thank Nelly Garduño and Iza Kornblum for their 36 technical assistance and Fernando Augusto for artwork. J.S.T. is an Investigator and 37 F.R-F. is a Postdoctoral Research Associate in the Howard Hughes Medical Institute. 38 This research was supported by NIH grant NIGMS K99GM132557 to F.R-F., VA 39 BLR&D CDA grant IK2BX002531 to T.E.B., NIH grant R01MH080297 and WPI program 40 for IIIS to R.W.G., as well as funding from Howard Hughes Medical Institute to J.S.T. 41 The contents of this manuscript do not represent the views of the U.S. Department of 42 Veterans Affairs or the United States Government. 43 44 ABSTRACT 45 46 Patients with sleeping sickness, caused by the parasite, Trypanosoma brucei, have 47 disruptions in both sleep timing and sleep architecture. However, the underlying cause 48 of these sleep disturbances is not well understood. Here we assessed the sleep 49 architecture of male mice infected with T. brucei and found that infected mice had 50 drastically altered sleep patterns. Interestingly, T. brucei infected mice also had a 51 reduced homeostatic sleep response to sleep deprivation, a response modulated by the 52 adenosine system. We found that infected mice had a reduced electrophysiological 53 response to an adenosine receptor antagonist and increased adenosine receptor gene 54 expression. Although the mechanism by which T. brucei infection causes these changes 55 remains to be determined, our findings suggest that the symptoms of sleeping sickness 56 may be due to alterations in homeostatic adenosine signaling. 57 58 59 SIGNIFICANCE STATEMENT 60 61 Sleeping sickness is a fatal disease that disrupts the circadian clock, causes disordered 62 temperature regulation, and induces sleep disturbance. To examine the neurological 63 effects of infection in the absence of other symptoms, in this study we used a mouse 64 model of sleeping sickness in which the acute infection was treated but brain infection 65 remained. Using this model, we evaluated the effects of the sleeping sickness parasite, 66 T. brucei, on sleep patterns in mice, under both normal and sleep-deprived conditions. 67 Our findings suggest that signaling of adenosine, a neuromodulator involved in 68 mediating homeostatic sleep drive, may be reduced in infected mice. 1 69 INTRODUCTION 70 Sleeping sickness (human African trypanosomiasis) is a disease endemic to sub- 71 Saharan Africa. It is caused by the parasite Trypanosoma brucei, which is transmitted to 72 humans by the tsetse fly (Franco et al., 2014). Sleeping sickness occurs in two phases. 73 In the first, hemolymphatic phase, T. brucei parasites are primarily found in the 74 bloodstream, interstitial spaces of peripheral organs, and lymphatic system (Caljon et 75 al., 2016; Capewell et al., 2016; Trindade et al., 2016). The main symptoms during this 76 first phase of the disease include fever, fatigue, and pain. In the second, meninge- 77 encephalitic stage, the parasites invade the central nervous system and cause 78 psychiatric symptoms as well as the progressive disruption of circadian rhythms, 79 including altered hormonal secretion, body temperature rhythms, daytime somnolence, 80 and nighttime insomnia (Buguet et al., 2001; Blum et al., 2006; Tesoriero et al., 2019). 81 In humans, sleep can be divided into 4 stages (3 sub-stages of non-rapid eye 82 movement [NREM] sleep (stage 3-4 also called Slow Wave Sleep [SWS]) and Rapid 83 Eye Movement [REM] sleep. These stages can be delineated by differences in brain 84 activity as measured by electroencephalography (EEG) and other physiological 85 parameters, such as muscle and eye movements (Jafari and Mohsenin, 2010). In 86 addition to changes in sleep timing, sleeping sickness patients have altered sleep 87 architecture, with REM episodes occurring immediately after sleep onset (SOREM) 88 instead of after NREM (Buguet et al., 2001; Buguet et al., 2005). This change in sleep 89 structure is similar to what is seen with narcolepsy (Nishino and Mignot, 1997; Fujiki et 90 al., 2009). Interestingly, while neither sleeping sickness nor narcolepsy causes 91 increased total sleep across the 24 h period (Dantz et al., 1994; Buguet et al., 2001), 2 92 narcoleptic patients do not have altered circadian rhythms (Dantz et al., 1994). T. brucei 93 is also distinct from other infections, which tend to increase sleep (Krueger and Opp, 94 2016; Tesoriero et al., 2019). How the T. brucei parasite produces these specific 95 alterations to the sleep system remains an open question (Lundkvist et al., 2004). 96 Sleep is regulated by interactions of the circadian system with a complex 97 homeostatic network that balances sleep need with arousal (Borbely et al., 2016). 98 Although there are many signals involved in maintaining arousal, an increase in 99 extracellular adenosine during wakefulness is thought to be a primary driver of both 100 homeostatic sleep need (Porkka-Heiskanen et al., 1997; Saper et al., 2005; Bjorness et 101 al., 2016; Bringmann, 2018) and motivation-related arousal (Lazarus et al., 2019). In 102 addition, allostatic mechanisms, such as the production of somnogens during infection, 103 also promote sleep (Bringmann, 2018; Toda et al., 2019). We previously showed that T. 104 brucei infection shortens the period of circadian behavioral activity in mice and disrupts 105 the molecular circadian clock within the suprachiasmatic nucleus (SCN) of the 106 hypothalamus (Rijo-Ferreira et al., 2018). However, the effects of T. brucei on 107 homeostatic drivers of sleep are unclear. 108 The purpose of the present study was to examine the effects of T. brucei 109 infection on sleep architecture in a mouse model of sleeping sickness. We found that, 110 similarly to the human infection, T. brucei infected mice had altered sleep architecture. 111 Interestingly, infection reduced the ability of mice to achieve or maintain REM sleep. In 112 addition, infected mice lacked a response to sleep deprivation, which may indicate a 113 change in their ability to achieve sleep or reduced sleep drive in the face of homeostatic 114 challenge. Electrophysiological experiments and quantification of gene expression 3 115 suggested that these behavioral changes were not due solely to inflammation induced 116 by infection, but rather may be caused by altered homeostatic adenosine signaling. 117 118 MATERIALS AND METHODS 119 Ethics statement 120 All animal care and experimental procedures were performed in accordance with 121 University of Texas Southwestern Medical Center (UTSW) IACUC guidelines, approved 122 by the Ethical Review Committee at the University of Southwestern Medical Center. 123 Housing and Surgical Procedures 124 Adult (8-12-week-old) male C57BL/6J mice from the UT Southwestern Medical 125 Center Mouse Breeding Core Facility were housed in standard mouse cages with food 126 and water provided ad libitum. Cages were in a temperature-controlled environment in a 127 T24 (12:12) LD cycle. To determine sleep/waking activity, EEG and EMG electrodes 128 were surgically implanted as described previously (Bjorness et al., 2009). Briefly, mice 129 were anesthetized with isoflurane and the scalp was sheared and cleaned. Mice were 130 then placed in a stereotax (Kopf, Tujunga, CA) and four holes were drilled in the skull. 131 Two EEG electrodes (Plastics One, Roanoke, VA) were placed bilaterally over the 132 frontal cortex (AP +1.7 mm, ML +/-1.77mm) and two electrodes were placed bilaterally 133 over the parietal cortex (AP -1.7 mm, ML +/-2mm). Two EMG electrodes (Plastics One, 134 Roanoke, VA) were placed bilaterally into the nuchal musculature. Electrode pins were 135 threaded into a 6-pin pedestal and affixed to the skull with dental adhesive (Fisher, 136 Pittsburgh, PA). After the surgery, the implant base was coated with antibiotic and 4 137 animals were given Buprenex (0.1 ml, IP) for analgesia. Animals were given 14 days to 138 recover from surgery prior to tether adaption and were housed singly following surgery. 139 Infection and Suramin Treatment 140 Infections were performed by intraperitoneal (i.p.) injection of 2000 Trypanosoma 141 brucei brucei AnTat 1.1E parasites between ZT9-12 (Zeitgeber time, ZT, 3-hour interval 142 before lights are off) (Rijo-Ferreira et al., 2018).
Recommended publications
  • The Neurobiology of Narcolepsy-Cataplexy
    Progress in Neurobiology Vol. 41, pp. 533 to 541, 1993 0301-0082/93/$24.00 Printed in Great Britain. All rights reserved © 1993 Pergamon Press Ltd THE NEUROBIOLOGY OF NARCOLEPSY-CATAPLEXY MICHAEL S. ALDRICH Department of Neurology, Sleep Disorders Center, University of Michigan Medical Center, Ann Arbor, MI, U.S.A. (Received 17 July 1992) CONTENTS 1. Introduction 533 2. Clinical aspects 533 2.1. Sleepiness and sleep attacks 533 2.2. Cataplexy and related symptoms 534 2.3. Clinical variants 534 2.3.1. Narcolepsy without cataplexy 534 2.3.2. Idiopathic hypersomnia 534 2.3.3. Symptomatic narcolepsy 534 2.4. Treatment 534 3. Pathophysiology 535 4. Neurobiological studies 535 4.1. The canine model of narcolepsy 535 4.2. Pharmacology of human cataplexy 537 4.3. Postmortem studies 537 5. Genetic and family studies 537 6. Summary and conclusions 539 References 539 1. INTRODUCTION 2. CLINICAL ASPECTS Narcolepsy is a specific neurological disorder Narcolepsy has a prevalence that varies worldwide characterized by excessive sleepiness that cannot be from as little as 0.0002% in Israel to 0.16% in Japan; fully relieved with any amount of sleep and by in North America and Europe the prevalence is about abnormalities of rapid eye movement (REM) 0.03-0.06% (Dement et al., 1972; Honda, 1979; Lavie sleep. About two-thirds of patients also have brief and Peled, 1987). The onset of narcoleptic symptoms, episodes of muscle weakness usually brought on by usually in the second or third decade of life, may emotion, referred to as cataplexy. The disorder gener- occur over a few days or weeks or it may be so ally begins in adolescence and continues throughout gradual that the loss of full alertness is unrecognized life.
    [Show full text]
  • Autophagy in Trypanosomatids
    Cells 2012, 1, 346-371; doi:10.3390/cells1030346 OPEN ACCESS cells ISSN 2073-4409 www.mdpi.com/journal/cells Review Autophagy in Trypanosomatids Ana Brennand 1,†, Eva Rico 2,†,‡ and Paul A. M. Michels 1,* 1 Research Unit for Tropical Diseases, de Duve Institute, Université catholique de Louvain, Avenue Hippocrate 74, postal box B1.74.01, B-1200 Brussels, Belgium; E-Mail: [email protected] 2 Department of Biochemistry and Molecular Biology, University Campus, University of Alcalá, Alcalá de Henares, Madrid, 28871, Spain; E-Mail: [email protected] † These authors contributed equally to this work. ‡ Present Address: Centre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, King’s Buildings, University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, UK. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +32-2-7647473; Fax: +32-2-7626853. Received: 28 June 2012; in revised form: 14 July 2012 / Accepted: 16 July 2012 / Published: 27 July 2012 Abstract: Autophagy is a ubiquitous eukaryotic process that also occurs in trypanosomatid parasites, protist organisms belonging to the supergroup Excavata, distinct from the supergroup Opistokontha that includes mammals and fungi. Half of the known yeast and mammalian AuTophaGy (ATG) proteins were detected in trypanosomatids, although with low sequence conservation. Trypanosomatids such as Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are responsible for serious tropical diseases in humans. The parasites are transmitted by insects and, consequently, have a complicated life cycle during which they undergo dramatic morphological and metabolic transformations to adapt to the different environments.
    [Show full text]
  • COVID-19 Mrna Pfizer- Biontech Vaccine Analysis Print
    COVID-19 mRNA Pfizer- BioNTech Vaccine Analysis Print All UK spontaneous reports received between 9/12/20 and 22/09/21 for mRNA Pfizer/BioNTech vaccine. A report of a suspected ADR to the Yellow Card scheme does not necessarily mean that it was caused by the vaccine, only that the reporter has a suspicion it may have. Underlying or previously undiagnosed illness unrelated to vaccination can also be factors in such reports. The relative number and nature of reports should therefore not be used to compare the safety of the different vaccines. All reports are kept under continual review in order to identify possible new risks. Report Run Date: 24-Sep-2021, Page 1 Case Series Drug Analysis Print Name: COVID-19 mRNA Pfizer- BioNTech vaccine analysis print Report Run Date: 24-Sep-2021 Data Lock Date: 22-Sep-2021 18:30:09 MedDRA Version: MedDRA 24.0 Reaction Name Total Fatal Blood disorders Anaemia deficiencies Anaemia folate deficiency 1 0 Anaemia vitamin B12 deficiency 2 0 Deficiency anaemia 1 0 Iron deficiency anaemia 6 0 Anaemias NEC Anaemia 97 0 Anaemia macrocytic 1 0 Anaemia megaloblastic 1 0 Autoimmune anaemia 2 0 Blood loss anaemia 1 0 Microcytic anaemia 1 0 Anaemias haemolytic NEC Coombs negative haemolytic anaemia 1 0 Haemolytic anaemia 6 0 Anaemias haemolytic immune Autoimmune haemolytic anaemia 9 0 Anaemias haemolytic mechanical factor Microangiopathic haemolytic anaemia 1 0 Bleeding tendencies Haemorrhagic diathesis 1 0 Increased tendency to bruise 35 0 Spontaneous haematoma 2 0 Coagulation factor deficiencies Acquired haemophilia
    [Show full text]
  • Diseases of the Digestive System (KOO-K93)
    CHAPTER XI Diseases of the digestive system (KOO-K93) Diseases of oral cavity, salivary glands and jaws (KOO-K14) lijell Diseases of pulp and periapical tissues 1m Dentofacial anomalies [including malocclusion] Excludes: hemifacial atrophy or hypertrophy (Q67.4) K07 .0 Major anomalies of jaw size Hyperplasia, hypoplasia: • mandibular • maxillary Macrognathism (mandibular)(maxillary) Micrognathism (mandibular)( maxillary) Excludes: acromegaly (E22.0) Robin's syndrome (087.07) K07 .1 Anomalies of jaw-cranial base relationship Asymmetry of jaw Prognathism (mandibular)( maxillary) Retrognathism (mandibular)(maxillary) K07.2 Anomalies of dental arch relationship Cross bite (anterior)(posterior) Dis to-occlusion Mesio-occlusion Midline deviation of dental arch Openbite (anterior )(posterior) Overbite (excessive): • deep • horizontal • vertical Overjet Posterior lingual occlusion of mandibular teeth 289 ICO-N A K07.3 Anomalies of tooth position Crowding Diastema Displacement of tooth or teeth Rotation Spacing, abnormal Transposition Impacted or embedded teeth with abnormal position of such teeth or adjacent teeth K07.4 Malocclusion, unspecified K07.5 Dentofacial functional abnormalities Abnormal jaw closure Malocclusion due to: • abnormal swallowing • mouth breathing • tongue, lip or finger habits K07.6 Temporomandibular joint disorders Costen's complex or syndrome Derangement of temporomandibular joint Snapping jaw Temporomandibular joint-pain-dysfunction syndrome Excludes: current temporomandibular joint: • dislocation (S03.0) • strain (S03.4) K07.8 Other dentofacial anomalies K07.9 Dentofacial anomaly, unspecified 1m Stomatitis and related lesions K12.0 Recurrent oral aphthae Aphthous stomatitis (major)(minor) Bednar's aphthae Periadenitis mucosa necrotica recurrens Recurrent aphthous ulcer Stomatitis herpetiformis 290 DISEASES OF THE DIGESTIVE SYSTEM Diseases of oesophagus, stomach and duodenum (K20-K31) Ill Oesophagitis Abscess of oesophagus Oesophagitis: • NOS • chemical • peptic Use additional external cause code (Chapter XX), if desired, to identify cause.
    [Show full text]
  • The Battle Is Not Over Until It Is Won
    HUMAN AFRICAN TRYPANOSOMIASIS SLEEPING SICKNESS The battle is not over until it is won Sleeping sickness, or human African trypa- melarsoprol. The latter, however, is still the nosomiasis, threatens millions of people in first-line treatment for the less commonT.b. 36 countries across sub-Saharan Africa. The rhodesiense HAT. Democratic Republic of the Congo bears the To contribute to the WHO elimination goal, a brunt, accounting for 83% of all cases. In the ‘test and treat’ strategy that would be imple- 1960s there were less than 5,000 patients mented at the primary healthcare level is on suffering from the disease in the whole of the the horizon, with potential simple oral pills continent. However, the end of the 20th cen- for both the early and late stage as well as tury – with internal conflict, competing health both types of HAT, that are currently in devel- priorities, and decolonization – witnessed a opment, along with new rapid diagnostics, halt in the successful control methods, and which together would remove the need for the number of cases reported rose painful and dangerous lumbar punc- steeply, peaking in 1998 with tures. This would mean that rural over 37,000 cases reported in health centres, rather than hos- that year. Nowadays, thanks pitals, will play an increasingly to the combined efforts of important role, especially as the WHO, National Sleeping number of reported cases con- Sickness Control Pro- tinues to dwindle. grammes, NGOs and other partners, the disease has once more been brought under control, and since 2010 the number of reported cases has fallen below 8,000.
    [Show full text]
  • Program and Abstracts
    Seventy 2019 years of Soixante-dix AU/ISCTRC Années de 1949 l’UA / CSIRLT 35TH GENERAL CONFERENCE OF THE INTERNATIONAL SCIENTIFIC COUNCIL FOR TRYPANOSOMIASIS RESEARCH AND CONTROL (ISCTRC) AND 18TH PATTEC NATIONAL COORDINATORS MEETING PROGRAMME AND ABSTRACTS BOOK 35TH GENERAL CONFERENCE OF THE INTERNATIONAL SCIENTIFIC COUNCIL FOR TRYPANOSOMIASIS RESEARCH AND CONTROL (ISCTRC) AND 18TH PATTEC NATIONAL COORDINATORS MEETING PROGRAMME AND ABSTRACTS BOOK ABOUT THE CONFERENCE Theme of the Conference Impact of African Trypanosomiasis on Human and Animal Health, Sustainable Agriculture and Rural Development in the face of challenges to sustainable investment in AAT control and HAT elimination”Members of the Scientific Committee The members of the 35th ISCTRC Scientific Committee that were appointed by the Director of AU-IBAR were drawn from various institutions working on Tsetse and Trypanosomiasis. The committee received and considered 140 abstracts addressing the various sub- themes of the conference. Prof. Ahmed Elsawalhy, Director of AU-IBAR, Chairperson Dr. James Wabacha, ISCTRC Secretary, Member Dr. Gift Wanda, Member Dr. Daniel Masiga, Member Dr. Jose Ramon Franco Rapporteur and Moderators Rapporteur General Grace Mulira Deputy Rapporteur General Njelembo Mbewe Moderators and rapporteurs for the various thematic sessions are as per the programme Presentation guidelines Allocated time for presentations: Each presentation will be allocated 10 minutes and 5 minutes for discussion. Viewing of posters There will be continuous viewing of the posters. The presenters for the posters will be at the stands during the coffee/tea breaks. There will be general discussion on the posters in the plenary on Thursday, 26th September 2019. Uploading of presentations in the conference computer Presenters who will be making presentation during the first day are IV requested to upload their presentation during registration on Sunday.
    [Show full text]
  • Somnology-Jr-Book.Pdf
    1 To Grace Zamudio and Zoe Lee-Chiong. 2 Preface Carpe noctem. Teofilo Lee-Chiong MD Professor of Medicine Division of Sleep Medicine National Jewish Health Denver, Colorado University of Colorado Denver School of Medicine Denver, Colorado Chief Medical Liaison Philips Respironics Murrysville, Pennsylvania 3 Abbreviations AHI Apnea-hypopnea index BPAP Bi-level positive airway pressure CPAP Continuous positive airway pressure CSA Central sleep apnea ECG Electrocardiography EEG Electroencephalography EMG Electromyography EOG Electro-oculography FEV1 Forced expiratory volume in 1 second GABA Gamma-aminobutyric acid N1 NREM stage 1 sleep N2 NREM stage 2 sleep N3 NREM stages 3 (and 4) sleep NREM Non-rapid eye movement O2 Oxygen OSA Obstructive sleep apnea PaCO2 Partial pressure of arterial carbon dioxide PaO2 Partial pressure of arterial oxygen REM Rapid eye movement sleep SaO2 Oxygen saturation SOREMP Sleep onset REM period 4 Table of contents Introduction 15 Neurobiology of sleep 16 Neural systems generating wakefulness 16 Neural systems generating NREM sleep 16 Neural systems generating REM sleep 16 Main neurotransmitters 17 Acetylcholine 17 Adenosine 17 Dopamine 17 Gamma-aminobutyric acid 17 Glutamate 17 Glycine 17 Histamine 18 Hypocretin 18 Melatonin 18 Norepinephrine 18 Serotonin 18 Physiology during sleep 19 Autonomic nervous system 19 Respiratory system 19 Respiratory patterns 19 Cardiovascular system 19 Gastrointestinal system 20 Renal and genito-urinary systems 20 Endocrine system 20 Growth hormone 20 Thyroid stimulating hormone
    [Show full text]
  • Section B – Abstracts
    ISSN 0142-193X TSETSE AND TRYPANOSOMIASIS INFORMATION QUARTERLY Volume 22 Part 1, 1999 Numbers 10713–10823 DFID Cirad-emvt 1999 Tsetse and Trypanosomiasis Information Quarterly SECTION A – NEWS PROGRAMME AGAINST AFRICAN TRYPANOSOMIASIS Fourth Meeting of PAAT Programme Committee The fourth meeting of the PAAT Programme Committee was convened at IAEA Headquarters, Vienna, Austria, from 25 to 27 November 1998. The objective of meetings of the PAAT Committee is, on the basis of technical and scientific advice forwarded from the Advisory Group Co-ordinators and the Liaison Officers, to provide the focus for collaborative efforts to alleviate trypanosomiasis in Africa. Discussions at the current meeting were largely devoted to matters arising from the meeting of the PAAT Advisory Group Co-ordinators convened in Harare, Zimbabwe, October 1998 (see TTIQ, 21 (4)). Progress since the last meeting was reviewed. This included: ISCTRC representation on the Programme Committee and increased donor involvement; considerable progress on the development of the information systems for both animal and human trypanosomiasis (both the prototype PAAT-IS for animal trypanosomiasis and the CD-ROM-based information system developed by WHO for the human disease were demonstrated and the need for cross-linkages between the two was stressed); evaluation of the socio-economic impact of trypanosomiasis and the identification of priority control strategies; development of position papers on technical and policy aspects of the PAAT following open discussion via e-mail (that on drug resistance having been published as the first in the new PAAT Technical and Scientific Series); production and distribution of a glossy brochure announcing PAAT; and initiation of a quarterly PAAT Newsletter.
    [Show full text]
  • A Comparison of Idiopathic Hypersomnia and Narcolepsy-Cataplexy Using Self Report Measures and Sleep Diary Data
    57676ournal ofNeurology, Neurosurgery, and Psychiatry 1996;60:576-578 SHORT REPORT J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.60.5.576 on 1 May 1996. Downloaded from A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data Dorothy Bruck, J D Parkes Abstract Published data comparing patients with IH Eighteen patients with idiopathic hyper- and patients with NLS outside the sleep labo- somnia (IH) were compared with 50 ratory are scarce. Using self report question- patients with the narcoleptic syndrome of naires and sleep diary data our aim was to cataplexy and daytime sleepiness (NLS) determine the extent of group differences and using self report questionnaires and a which variables best discriminated between IH diary of sleep/wake patterns. The IH and NLS. group reported more consolidated noc- turnal sleep, a lower propensity to nap, greater refreshment after naps, and a Patients and methods greater improvement in excessive day- DIAGNOSTIC CRITERIA time sleepiness since onset than the NLS Idiopathic hypersomnia group. In IH, the onset of excessive day- Patients were selected with a complaint of time sleepiness was predominantly asso- excessive daytime sleepiness without cataplexy ciated with familial inheritance or a viral and with no evidence of any medical, psycho- illness. Two variables-number of logical, drug related, or respiratory disorder. reported awakenings during nocturnal All patients met diagnostic criteria ascertained sleep and the reported change in sleepi- from questionnaire responses: Epworth sleepi- ness since onset-provided maximum ness scale score8 > 13; duration of excessive discrimination between the IH and NLS daytime sleepiness > five years, profile of groups.
    [Show full text]
  • Narcolepsy-1111 28/11/11 9:15 PM Page 1
    SHF-Narcolepsy-1111 28/11/11 9:15 PM Page 1 Narcolepsy Important Things to Know About Narcolepsy • It is a disorder of excessive daytime sleepiness • It may have other symptoms that involve a loss of muscle function • Symptoms can be treated • It can occur at any age but often starts in early adulthood • Diagnosis is best done by a sleep specialist or neurologist What is narcolepsy? hallucinations. You may see or hear things that are not really there, especially if you are drowsy. Narcolepsy is a chronic neurological disorder of excessive daytime sleepiness. It may occur with other symptoms What causes narcolepsy? such as cataplexy, sleep paralysis and hallucinations. • All people with narcolepsy have excessive drowsiness. The part of the brain which controls falling asleep You may have a lack of energy. Strong urges to nap functions abnormally. During the day when normally can happen at any time of the day. Naps might last for awake and active, you might fall asleep with little minutes or up to an hour or more. After a nap you warning, rapidly going into a stage of sleep called Rapid may be alert for several hours. While this may happen Eye Movement (or REM) sleep. During normal REM sleep every day it is not because you aren’t sleeping enough there is both dreaming and temporary loss of muscle at night. tone. With the shift to REM sleep in narcolepsy, there might be hallucinations, cataplexy and sleep paralysis. It • Cataplexy is a sudden loss of muscle function while is thought that narcolepsy is related to lack of a brain conscious.
    [Show full text]
  • The Trypanosomiases
    SEMINAR Seminar The trypanosomiases Michael P Barrett, Richard J S Burchmore, August Stich, Julio O Lazzari, Alberto Carlos Frasch, Juan José Cazzulo, Sanjeev Krishna The trypanosomiases consist of a group of important animal and human diseases caused by parasitic protozoa of the genus Trypanosoma. In sub-Saharan Africa, the final decade of the 20th century witnessed an alarming resurgence in sleeping sickness (human African trypanosomiasis). In South and Central America, Chagas’ disease (American trypanosomiasis) remains one of the most prevalent infectious diseases. Arthropod vectors transmit African and American trypanosomiases, and disease containment through insect control programmes is an achievable goal. Chemotherapy is available for both diseases, but existing drugs are far from ideal. The trypanosomes are some of the earliest diverging members of the Eukaryotae and share several biochemical peculiarities that have stimulated research into new drug targets. However, differences in the ways in which trypanosome species interact with their hosts have frustrated efforts to design drugs effective against both species. Growth in recognition of these neglected diseases might result in progress towards control through increased funding for drug development and vector elimination. Parasitic protozoa infect hundreds of millions of people similarities and discrepancies in their biology, the diseases every year and are collectively some of the most important they cause, and approaches to their treatment and control. causes of human misery. The protozoan order Kineto- plastida includes the genus Trypanosoma, species that cause The parasites and their vectors some of the most neglected human diseases. Superficially, there are many similarities between There are many species of trypanosome, and the group trypanosome species and the diseases they cause (table).
    [Show full text]
  • Clinical Guide for Sleep Specialists: Diagnosing Narcolepsy
    CLINICIAN GUIDE 1 This brochure can help you: Table of Contents RECOGNIZE Narcolepsy Overview..................................................................... 4 possible manifestations of excessive daytime sleepiness, Narcolepsy Symptoms.................................................................... 5 1-3 the cardinal symptom of narcolepsy Pathophysiology of Narcolepsy.................................................. 6 SCREEN Neurobiology of Normal Wakefulness...................................... 6 all patients with manifestations of excessive daytime sleepiness Pathophysiology of Narcolepsy................................................... 6 for narcolepsy using validated screening tools4-7 Recognizing Potential Narcolepsy Patients............................. 8 DIAGNOSE Recognizing Excessive Daytime Sleepiness........................... 8 narcolepsy through a complete clinical interview Recognizing Cataplexy................................................................... 9 and sleep laboratory testing1 Screening Your Patients................................................................ 10 Epworth Sleepiness Scale.............................................................. 10 Swiss Narcolepsy Scale...................................................................11 Diagnosing Narcolepsy..................................................................12 Clinical Interview............................................................................... 12 Sleep Laboratory Testing..............................................................
    [Show full text]